Skip to main content
TipRanks
Go Ultimate75% OFF

Corteva (2X0) AI Stock Analysis

0 Followers
CH:2X0

Corteva

(BX Swiss:2X0)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
New-product momentumStrong volume growth across regions indicates that Corteva’s innovation pipeline is translating into customer adoption. Continued uptake of new products can support market-share gains, improve product mix, and partly offset pricing pressure over the next several quarters.
Negative Factors
Weak recent cash conversionThe sharp deterioration in operating and free cash flow creates a meaningful quality-of-earnings concern. If cash conversion remains weak, Corteva may have less flexibility to fund R&D, dividends, capital spending, or strategic actions from internally generated resources.

Corteva (2X0) vs. iShares MSCI Switzerland ETF (EWL)

-5%0%5%10%15%20%CH:2X0+11.58%EWL+16.05%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
CHF 6.29B
Dividend Yield
4.80%
Average Volume (3M)
290
Price to Earnings (P/E)
7.8
Beta (1Y)
1.37
Revenue Growth
-5.96%
EPS Growth
-57.21%
Country
Switzerland
Employees
21,500
Sector
Basic Materials
Sector Strength
61
Industry
Agricultural Inputs

Corteva Business Overview & Revenue Model

Company Description

Corteva, Inc. operates in the agriculture business. The company operates through two segments, Seed and Crop Protection. The Seed segment develops and supplies advanced germplasm and traits that produce optimum yield for farms. It offers trait techno...

Corteva Earnings Call Summary

Earnings Call Date:Nov 11, 2026(Q3-2026)|% Change Since:0.00%|Next Earnings Date:Feb 03, 2027
Earnings Call SentimentNegative

The call presented strong execution, innovation, productivity and growth across North America, EMEA and Asia Pacific, supported by new product growth and expanded year-to-date margins. However, the significant deterioration in Brazil, elevated channel inventory, pricing pressure, lower full-year EBITDA guidance and an expected fourth-quarter EBITDA decline were central to the discussion. The negative Brazil-driven outlook outweighed the otherwise solid performance in the rest of the business.

Positive Updates

New Product Volumes Increased Across All Regions
New product volumes grew 20% in the quarter, with growth in every region, while pricing for this group of products was relatively stable. Year-to-date new product sales volume was up 14%.

Negative Updates

Third-Quarter Sales and EBITDA Declined
Third-quarter net sales were $1.6 billion, down 9% versus the prior year on both a reported and organic basis. Operating EBITDA was $222 million, down 17%, and operating EBITDA margin was 14%, down 140 basis points.

Company Guidance

Corteva updated 2026 stand-alone operating EBITDA guidance to a range of $1.1 billion to $1.125 billion, with full year operating EBITDA expected to be down 12% versus last year at the midpoint and operating EBITDA margin of about 15%; fourth quarter EBITDA is expected to be about half of 2025 levels on an adjusted pro forma basis, operating EPS is expected to be in the range of $0.76 to $0.80 per share, up about 3% at the midpoint, and the full year EBITDA impact related to elevated channel inventory is estimated at approximately $100 million. Fourth quarter revenue is expected to be around $2 billion, down year-over-year, with volumes generally flat year-over-year and pricing down high single digits; U.S. acetochlor is expected to contribute a fourth-quarter headwind closer to that $40-ish million level, with a little bit of it in the first quarter and no year-over-year headwinds expected by the second quarter of 2027. Corteva remains on track for a year-end cash position of about $1.5 billion, around $1 billion of financial debt, underlying fourth-quarter CapEx of about $50 million, and expects to grow the business in 2027.

Corteva Risk Analysis

Corteva disclosed 31 risk factors in its most recent earnings report. Corteva reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

0 New Risks

Corteva Peers Comparison

Overall Rating

UnderperformOutperform
Sector (61)

Financial Indicators

CH:2X0 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
CFCF77Outperform$18.30B8.8040.30%1.76%17.87%70.91%
Sector *61Neutral$10.43B7.12-0.05%2.87%2.86%-36.73%
ICLICL55Neutral$5.83B18.645.09%4.56%10.15%-15.98%
MOSMOS47Neutral$6.97B-16.48-3.78%4.01%0.02%-191.20%
FMCFMC42Neutral$810.46M-0.16-308.88%6.14%-21.99%-677.23%
BIOXBIOX38Underperform$13.40M-0.06-216.09%―-26.10%14.85%

* Basic Materials Sector Average

Performance Comparison

-50%0%50%CH:2X0CFFMCMOSICLBIOXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CH:2X0 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CH:2X0Corteva11.951.2411.58%
CFCf Industries Holdings, Inc.125.0945.5657.30%
FMCFMC Corp5.21-7.40-58.69%
MOSMosaic Co21.92-1.73-7.32%
ICLIcl Group Ltd.4.52-0.70-13.39%
BIOXBioceres Crop Solutions0.21-1.33-86.41%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.